Fluvoxamine Indications
Fluvoxamine is FDA-approved specifically for the treatment of Obsessive-Compulsive Disorder (OCD) in adults, though it is also used off-label for various anxiety disorders including social anxiety disorder, panic disorder, generalized anxiety disorder, and separation anxiety disorder in both adults and children. 1
FDA-Approved Indication
- Obsessive-Compulsive Disorder (OCD): Fluvoxamine maleate tablets are indicated for the treatment of obsessions and compulsions in patients with OCD as defined in DSM-III-R, where symptoms cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. 1
- The FDA approval was based on three 10-week trials in obsessive-compulsive outpatients, though effectiveness beyond 10 weeks has not been systematically evaluated in placebo-controlled trials. 1
- Fluvoxamine was the first SSRI registered for treatment of OCD in children. 2
Evidence-Based Off-Label Uses in Anxiety Disorders
Pediatric Anxiety Disorders (Ages 6-18)
- Social anxiety disorder, generalized anxiety disorder, separation anxiety disorder, and panic disorder: The American Academy of Child and Adolescent Psychiatry (AACAP) guidelines support the use of SSRIs as a class, including fluvoxamine, for these conditions in children and adolescents aged 6-18 years. 3
- Fluvoxamine demonstrated efficacy in well-controlled studies involving children and adolescents with OCD, social anxiety disorder, and other anxiety disorders. 2
Adult Anxiety Disorders
- Panic disorder: Fluvoxamine 100-300 mg/day for 6-8 weeks was as effective as imipramine and significantly more effective than placebo, with significant improvement evident as early as week 1 for some panic variables. 4, 5
- Social phobia (social anxiety disorder): Treatment with fluvoxamine ≤300 mg/day for ≥8 weeks improved symptoms of social phobia. 4
- Post-traumatic stress disorder (PTSD): Fluvoxamine showed improvements in PTSD symptoms in clinical trials. 2, 4
Obsessive-Compulsive Spectrum Disorders
Fluvoxamine has demonstrated efficacy in several obsessive-compulsive spectrum disorders, including:
- Binge eating disorder 2
- Bulimia nervosa 2
- Pathological gambling 2, 4
- Body dysmorphic disorder 2, 4
- Trichotillomania 4
- Kleptomania 4
- Compulsive buying 4
Depression
- While not the primary FDA indication, fluvoxamine has demonstrated consistent superiority over placebo in achieving treatment response and remission in depression, with efficacy comparable to other antidepressants including TCAs and other SSRIs. 6
Important Clinical Considerations
Dosing Characteristics
- Most SSRIs permit single daily dosing due to long elimination half-lives, but at any dose of fluvoxamine, youths may require twice-daily dosing due to its shorter half-life. 3
Drug Interaction Profile
- Fluvoxamine has greater potential for drug-drug interactions compared to other SSRIs, as it interacts with drugs metabolized by CYP1A2, CYP2C19, CYP2C9, CYP3A4, and CYP2D6. 3
- This contrasts with citalopram/escitalopram, which have the least effect on CYP450 isoenzymes and lower propensity for drug interactions. 3
Discontinuation Syndrome Risk
- Fluvoxamine has been associated with discontinuation syndrome (along with paroxetine and sertraline), characterized by dizziness, fatigue, sensory disturbances, anxiety, and other symptoms following missed doses or abrupt discontinuation. 3
- Gradual dose reduction rather than abrupt cessation is recommended. 1
NOT Indicated for COVID-19
- Recent high-quality trials (2023) demonstrated that fluvoxamine at both 50 mg and 100 mg twice daily does not reduce time to sustained recovery or prevent hospitalization in outpatients with mild to moderate COVID-19. 7, 8
- These findings do not support the use of fluvoxamine for COVID-19 treatment despite earlier meta-analyses suggesting potential benefit. 7, 8